Clinical Benefit with First-Line Immunotherapy in Advanced Hepatocellular Carcinoma
New data have shown a trend towards clinically meaningful improvements in survival and response rates and a favourable safety profile with first-line immunotherapy compared to current standard treatment for advanced hepatocellular carcinoma (HCC).